Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-08-31 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于董事、高级管理人员辞任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director and senior management personnel, specifically the resignation of Mr. Wang Hongqi from his roles as director and vice general manager. It includes details about the resignation's effect on the board and company operations, compliance with relevant laws and regulations, and expresses gratitude for the contributions made. There is no financial data, no mention of financial results, no report publication, or other types of filings. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-08-31 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2023年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed semi-annual tracking report for the first half of 2023 related to Shenzhen BGI Genomics Co., Ltd., prepared by CITIC Securities Co., Ltd. It includes extensive information on sponsorship work overview, company and shareholder commitments, regulatory compliance, and supervisory measures. The content is comprehensive, covering financial data, governance, regulatory reviews, and compliance issues, which aligns with a detailed interim or quarterly report rather than a brief announcement or a simple certification. The document length is about 15,000 characters, indicating it is a full report rather than a short notice. The presence of financial performance data for the period January to June 2023, and detailed management and regulatory information, supports classification as an Interim / Quarterly Report (IR). H1 2023
2023-08-31 Chinese
关于控股股东部分股份解除质押及再质押的公告
Regulatory Filings Classification · 100% confidence The document is an announcement regarding the release and re-pledging of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares involved, pledge dates, pledgees, and the impact on the company's shareholding structure. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledge status and related shareholder information. It does not fit into financial reports, earnings releases, or management reports. It is a typical share pledge update, which is best classified under Regulatory Filings (RNS) as it is a compliance disclosure about share pledges and related shareholder information.
2023-08-24 Chinese
关于全资子公司产品获得IVDR CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary's product obtaining IVDR CE certification, which is a regulatory approval for medical devices in the EU. The text includes details about the product, certification, market impact, and risk warnings. It does not contain financial statements, earnings data, or detailed management discussion. The document length is short (1807 characters) and is an announcement of a certification event rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-08-22 Chinese
独立董事关于第三届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 19th meeting of the third board of directors of Shenzhen BGI Genomics Co., Ltd. It includes independent opinions on the 2023 half-year fundraising fund storage and usage report, related party fund occupation and external guarantees for the first half of 2023, and an acquisition transaction involving a related party. The document is a formal opinion letter from independent directors regarding board meeting agenda items, focusing on compliance, fairness, and legality of these matters. It does not contain full financial statements or detailed financial performance data, nor is it a report publication announcement or a certification letter. It is a board/management related document concerning board meeting matters and independent directors' opinions. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short (1692 characters), consistent with an opinion letter rather than a full report.
2023-08-11 Chinese
第三届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 19th meeting of the 3rd Board of Directors of Shenzhen BGI Genomics Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items such as approval of the 2023 semi-annual report, a special report on the use of raised funds, and a related-party acquisition transaction. The document does not contain the full semi-annual report or detailed financial statements but rather announces the board's approval of these reports and transactions. The document length is short (1739 characters) and it references that the full reports are disclosed elsewhere (on the CNINFO website and newspapers). This fits the pattern of a Board/Management Information announcement, specifically about board meeting resolutions and approvals. Therefore, the appropriate classification is MANG (Board/Management Information).
2023-08-11 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.